What is the appropriate approach to diagnosing and treating thalassemia?

Approach to Diagnosis and Treatment of Thalassemia

Diagnostic Workup

Begin with complete blood count showing microcytic hypochromic anemia (low MCV), then perform hemoglobin electrophoresis or HPLC to quantify HbA2 and HbF levels, which are elevated in β-thalassemia trait and major. 1, 2

Initial Laboratory Assessment

• Order CBC with peripheral smear looking specifically for target cells, microcytosis (MCV typically <70 fL), and hypochromia 2
• Measure hemoglobin electrophoresis or HPLC to identify elevated HbA2 (>3.5%) in β-thalassemia trait and elevated HbF in β-thalassemia major 1, 2
• Check reticulocyte count to assess bone marrow response to anemia 2
• Obtain iron studies (ferritin, TSAT, serum iron) to exclude iron deficiency, which can mask thalassemia trait 3
• Key distinguishing feature: Low MCV with RDW ≤14.0% suggests thalassemia minor, while low MCV with RDW >14.0% suggests iron deficiency 3

Genetic Confirmation

• Perform DNA analysis for specific globin gene mutations once phenotype suggests thalassemia 1, 4, 2
• Use accurate circular consensus long-read sequencing for detecting rare thalassemia variants when conventional molecular analysis is inconclusive 5
• For prenatal diagnosis in at-risk couples, obtain fetal DNA samples via amniocentesis or chorionic villus sampling to detect single point mutations 2, 6

Classification After Diagnosis

• Transfusion-dependent thalassemia (TDT): Requires regular transfusions for survival, typically β-thalassemia major 7, 1
• Non-transfusion-dependent thalassemia (NTDT): <8 transfusions or ≥6 weeks between transfusions in 1 year, includes thalassemia intermedia 8
• Thalassemia minor/trait: Asymptomatic carriers with mild microcytic anemia 9

---

Treatment Algorithm by Disease Severity

Thalassemia Major (Transfusion-Dependent)

Initiate regular blood transfusion therapy every 2-4 weeks to maintain pre-transfusion hemoglobin >9-10 g/dL, combined with mandatory iron chelation therapy to prevent fatal iron overload. 1, 2

Transfusion Protocol

• Transfuse packed red blood cells every 2-4 weeks targeting pre-transfusion Hb 9-10 g/dL and post-transfusion Hb 13-14 g/dL 1, 2
• Use leukoreduced blood products to minimize alloimmunization 10
• Consider extended red cell antigen matching in chronically transfused patients 10

Iron Chelation (Mandatory with Regular Transfusions)

• Start iron chelation when ferritin reaches 1000 μg/L or after 10-20 transfusions 1, 2
• First-line oral chelator: Deferasirox (starting dose 20-30 mg/kg/day) 2
• Alternative: Deferiprone (75-100 mg/kg/day divided in 3 doses) 2
• Monitor ferritin levels every 3 months, targeting ferritin <1000 μg/L 1, 2
• Obtain liver MRI (T2*) annually to assess cardiac and hepatic iron deposition 10, 1

Curative Treatment Options

• Hematopoietic stem cell transplantation (HSCT) is the only established curative therapy and should be offered as soon as possible to young patients with an HLA-identical sibling donor before iron-related organ damage develops 7
• Best outcomes: Disease-free survival 96% in children <14 years with matched sibling donor and low-risk status (no hepatomegaly, no portal fibrosis, adequate chelation) 7
• Transplant-related mortality <5% in young low-risk children with matched sibling donor 7
• Consider matched unrelated donor or cord blood transplantation when sibling donor unavailable 7, 2
• Gene therapy is emerging as curative option but currently limited to specialized centers 7, 11, 2

Thalassemia Intermedia (Non-Transfusion-Dependent)

Manage with folic acid supplementation (1 mg daily), monitor hemoglobin regularly, and transfuse only when symptomatic or Hb drops below 7 g/dL to avoid suppressing endogenous erythropoiesis. 9, 2

• Provide folic acid 1 mg daily to support erythropoiesis 9, 2
• Reserve transfusions for symptomatic anemia, growth failure, or complications 9, 2
• Consider splenectomy if hypersplenism causes worsening anemia or thrombocytopenia 9, 2
• Monitor for iron overload even without regular transfusions, as increased intestinal iron absorption occurs 1, 2
• Consider hydroxyurea therapy to increase fetal hemoglobin production in selected cases 11, 9

Thalassemia Minor/Trait

• No treatment required; provide genetic counseling 9, 4
• Critical: Screen partner for thalassemia carrier status before pregnancy to assess risk of affected offspring 4, 6
• Avoid unnecessary iron supplementation unless true iron deficiency is documented 3, 4

---

Monitoring Protocol for Transfusion-Dependent Patients

Regular Laboratory Monitoring

• Check hemoglobin and ferritin every 3 months 1, 2
• Obtain liver function tests, renal function, and glucose every 6-12 months 1, 12
• Measure liver MRI T2* for iron quantification annually 10, 1
• Assess cardiac MRI T2* annually starting at age 10 years 1, 2

Endocrine Screening (Critical to Prevent Complications)

• Screen for growth and pubertal development every 6 months starting before age 10 years in transfusion-dependent patients 12
• Check thyroid function (TSH, free T4) annually 12
• Screen for diabetes with fasting glucose and HbA1c annually starting at age 10 years 12
• Assess bone density (DEXA scan) every 2 years starting at age 10-12 years 12
• Evaluate gonadal function (LH, FSH, testosterone/estradiol) annually during puberty 12
• Monitor for hypoparathyroidism with calcium and PTH if symptomatic 12

Cardiac Monitoring

• Perform echocardiography annually to assess cardiac function 1, 2
• Obtain cardiac MRI T2* annually; if T2* <20 ms, intensify iron chelation immediately 1, 2

---

Critical Pitfalls to Avoid

• Never delay HSCT in young children with matched sibling donors, as outcomes worsen significantly after age 14 years and with progressive iron overload 7
• Avoid over-transfusion above Hb 13-14 g/dL post-transfusion, as this suppresses endogenous erythropoiesis and increases iron loading 10, 1
• Never start regular transfusions without concurrent iron chelation planning, as iron overload causes fatal cardiac and hepatic complications 1, 2
• Do not diagnose thalassemia trait as iron deficiency and give unnecessary iron supplementation; always check hemoglobin electrophoresis when MCV is low with normal RDW 3, 4
• Failure to screen for endocrine complications leads to irreversible growth failure, delayed puberty, and osteoporosis 12
• Do not use restrictive transfusion strategy (Hb 7-8 g/dL) in thalassemia major, as chronic severe anemia causes bone deformities, extramedullary hematopoiesis, and growth failure 1, 2
• In couples where both partners are thalassemia carriers, mandatory prenatal diagnosis should be offered to prevent birth of affected children 4, 6